News & Updates
Filter by Specialty:
Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
A full, therapeutic dosing of anticoagulation flops for reducing the incidence of overall combined outcomes in noncritically ill patients hospitalized with COVID-19 as compared with prophylactic dosing, although there is a signal of benefit for mortality and disease progression with the therapeutic dosing, as shown in the FREEDOM COVID trial presented at ACC.23/WCC.
Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
23 Mar 2023
5-ASA maintenance therapy of little help in patients with newly diagnosed CD
Maintenance treatment with 5-aminosalicylates (5-ASA) in patients with newly diagnosed Crohn's disease (CD) does not appear to lead to better outcomes as compared with a watchful waiting approach, according to a study.
5-ASA maintenance therapy of little help in patients with newly diagnosed CD
23 Mar 2023
Response to therapy higher in clinical trial than real-world RCC patients
Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.
Response to therapy higher in clinical trial than real-world RCC patients
22 Mar 2023
Menopausal hormone therapy use carries increased T2DM risk
The use of menopausal hormone therapy (MHT), including the most prescribed agent tibolone, appears to contribute to an increase in the risk of type 2 diabetes mellitus (T2DM), as shown in a retrospective study.
Menopausal hormone therapy use carries increased T2DM risk
21 Mar 2023
PCSK9 inhibition tied to decreased psoriasis risk
Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway appears to be causally associated with a lower risk of psoriasis, regardless of the concentration levels of circulating low-density lipoprotein (LDL), according a two-sample Mendelian randomization study.